IPNews® – A U.S. District Court in Delaware recently ruled that Allergan’s patents related to its Sanctura XR drug are invalid. 

The ruling stems from a 2009 patent infringement complaint filed by Allergan against Watson Pharmaceuticals, in its attempts to prevent Watson from filing an abbreviated new drug application with the FDA for the generic version of Sanctura.  Allergan currently has two other patent infringement complaints filed against Watson.  To continue reading click: Allergan Loses Patents